Global Antisense & RNAi Therapeutics Market Size, Status and Forecast 2024-2031

Report ID: 1013376 | Published Date: Jan 2025 | No. of Page: 120 | Base Year: 2024 | Rating: 3.9 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Antisense & RNAi Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
        1.2.2 RNA Interference
        1.2.3 SiRNA
        1.2.4 MiRNA
        1.2.5 Antisense RNA
    1.3 Market by Application
        1.3.1 Global Antisense & RNAi Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
        1.3.2 Oncology
        1.3.3 Cardiovascular
        1.3.4 Renal
        1.3.5 Neurodegenerative
        1.3.6 Respiratory
        1.3.7 Genetic
        1.3.8 Infectious Diseases
    1.4 Study Objectives
    1.5 Years Considered

2 Global Growth Trends
    2.1 Global Antisense & RNAi Therapeutics Market Perspective (2016-2027)
    2.2 Antisense & RNAi Therapeutics Growth Trends by Regions
        2.2.1 Antisense & RNAi Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
        2.2.2 Antisense & RNAi Therapeutics Historic Market Share by Regions (2016-2021)
        2.2.3 Antisense & RNAi Therapeutics Forecasted Market Size by Regions (2022-2027)
    2.3 Antisense & RNAi Therapeutics Industry Dynamic
        2.3.1 Antisense & RNAi Therapeutics Market Trends
        2.3.2 Antisense & RNAi Therapeutics Market Drivers
        2.3.3 Antisense & RNAi Therapeutics Market Challenges
        2.3.4 Antisense & RNAi Therapeutics Market Restraints

3 Competition Landscape by Key Players
    3.1 Global Top Antisense & RNAi Therapeutics Players by Revenue
        3.1.1 Global Top Antisense & RNAi Therapeutics Players by Revenue (2016-2021)
        3.1.2 Global Antisense & RNAi Therapeutics Revenue Market Share by Players (2016-2021)
    3.2 Global Antisense & RNAi Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    3.3 Players Covered: Ranking by Antisense & RNAi Therapeutics Revenue
    3.4 Global Antisense & RNAi Therapeutics Market Concentration Ratio
        3.4.1 Global Antisense & RNAi Therapeutics Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Antisense & RNAi Therapeutics Revenue in 2020
    3.5 Antisense & RNAi Therapeutics Key Players Head office and Area Served
    3.6 Key Players Antisense & RNAi Therapeutics Product Solution and Service
    3.7 Date of Enter into Antisense & RNAi Therapeutics Market
    3.8 Mergers & Acquisitions, Expansion Plans

4 Antisense & RNAi Therapeutics Breakdown Data by Type
    4.1 Global Antisense & RNAi Therapeutics Historic Market Size by Type (2016-2021)
    4.2 Global Antisense & RNAi Therapeutics Forecasted Market Size by Type (2022-2027)

5 Antisense & RNAi Therapeutics Breakdown Data by Application
    5.1 Global Antisense & RNAi Therapeutics Historic Market Size by Application (2016-2021)
    5.2 Global Antisense & RNAi Therapeutics Forecasted Market Size by Application (2022-2027)

6 North America
    6.1 North America Antisense & RNAi Therapeutics Market Size (2016-2027)
    6.2 North America Antisense & RNAi Therapeutics Market Size by Type
        6.2.1 North America Antisense & RNAi Therapeutics Market Size by Type (2016-2021)
        6.2.2 North America Antisense & RNAi Therapeutics Market Size by Type (2022-2027)
        6.2.3 North America Antisense & RNAi Therapeutics Market Size by Type (2016-2027)
    6.3 North America Antisense & RNAi Therapeutics Market Size by Application
        6.3.1 North America Antisense & RNAi Therapeutics Market Size by Application (2016-2021)
        6.3.2 North America Antisense & RNAi Therapeutics Market Size by Application (2022-2027)
        6.3.3 North America Antisense & RNAi Therapeutics Market Size by Application (2016-2027)
    6.4 North America Antisense & RNAi Therapeutics Market Size by Country
        6.4.1 North America Antisense & RNAi Therapeutics Market Size by Country (2016-2021)
        6.4.2 North America Antisense & RNAi Therapeutics Market Size by Country (2022-2027)
        6.4.3 United States
        6.4.4 Canada

7 Europe
    7.1 Europe Antisense & RNAi Therapeutics Market Size (2016-2027)
    7.2 Europe Antisense & RNAi Therapeutics Market Size by Type
        7.2.1 Europe Antisense & RNAi Therapeutics Market Size by Type (2016-2021)
        7.2.2 Europe Antisense & RNAi Therapeutics Market Size by Type (2022-2027)
        7.2.3 Europe Antisense & RNAi Therapeutics Market Size by Type (2016-2027)
    7.3 Europe Antisense & RNAi Therapeutics Market Size by Application
        7.3.1 Europe Antisense & RNAi Therapeutics Market Size by Application (2016-2021)
        7.3.2 Europe Antisense & RNAi Therapeutics Market Size by Application (2022-2027)
        7.3.3 Europe Antisense & RNAi Therapeutics Market Size by Application (2016-2027)
    7.4 Europe Antisense & RNAi Therapeutics Market Size by Country
        7.4.1 Europe Antisense & RNAi Therapeutics Market Size by Country (2016-2021)
        7.4.2 Europe Antisense & RNAi Therapeutics Market Size by Country (2022-2027)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic

8 Asia-Pacific
    8.1 Asia-Pacific Antisense & RNAi Therapeutics Market Size (2016-2027)
    8.2 Asia-Pacific Antisense & RNAi Therapeutics Market Size by Type
        8.2.1 Asia-Pacific Antisense & RNAi Therapeutics Market Size by Type (2016-2021)
        8.2.2 Asia-Pacific Antisense & RNAi Therapeutics Market Size by Type (2022-2027)
        8.2.3 Asia-Pacific Antisense & RNAi Therapeutics Market Size by Type (2016-2027)
    8.3 Asia-Pacific Antisense & RNAi Therapeutics Market Size by Application
        8.3.1 Asia-Pacific Antisense & RNAi Therapeutics Market Size by Application (2016-2021)
        8.3.2 Asia-Pacific Antisense & RNAi Therapeutics Market Size by Application (2022-2027)
        8.3.3 Asia-Pacific Antisense & RNAi Therapeutics Market Size by Application (2016-2027)
    8.4 Asia-Pacific Antisense & RNAi Therapeutics Market Size by Region
        8.4.1 Asia-Pacific Antisense & RNAi Therapeutics Market Size by Region (2016-2021)
        8.4.2 Asia-Pacific Antisense & RNAi Therapeutics Market Size by Region (2022-2027)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia

9 Latin America
    9.1 Latin America Antisense & RNAi Therapeutics Market Size (2016-2027)
    9.2 Latin America Antisense & RNAi Therapeutics Market Size by Type
        9.2.1 Latin America Antisense & RNAi Therapeutics Market Size by Type (2016-2021)
        9.2.2 Latin America Antisense & RNAi Therapeutics Market Size by Type (2022-2027)
        9.2.3 Latin America Antisense & RNAi Therapeutics Market Size by Type (2016-2027)
    9.3 Latin America Antisense & RNAi Therapeutics Market Size by Application
        9.3.1 Latin America Antisense & RNAi Therapeutics Market Size by Application (2016-2021)
        9.3.2 Latin America Antisense & RNAi Therapeutics Market Size by Application (2022-2027)
        9.3.3 Latin America Antisense & RNAi Therapeutics Market Size by Application (2016-2027)
    9.4 Latin America Antisense & RNAi Therapeutics Market Size by Country
        9.4.1 Latin America Antisense & RNAi Therapeutics Market Size by Country (2016-2021)
        9.4.2 Latin America Antisense & RNAi Therapeutics Market Size by Country (2022-2027)
        9.4.3 Mexico
        9.4.4 Brazil

10 Middle East & Africa
    10.1 Middle East & Africa Antisense & RNAi Therapeutics Market Size (2016-2027)
    10.2 Middle East & Africa Antisense & RNAi Therapeutics Market Size by Type
        10.2.1 Middle East & Africa Antisense & RNAi Therapeutics Market Size by Type (2016-2021)
        10.2.2 Middle East & Africa Antisense & RNAi Therapeutics Market Size by Type (2022-2027)
        10.2.3 Middle East & Africa Antisense & RNAi Therapeutics Market Size by Type (2016-2027)
    10.3 Middle East & Africa Antisense & RNAi Therapeutics Market Size by Application
        10.3.1 Middle East & Africa Antisense & RNAi Therapeutics Market Size by Application (2016-2021)
        10.3.2 Middle East & Africa Antisense & RNAi Therapeutics Market Size by Application (2022-2027)
        10.3.3 Middle East & Africa Antisense & RNAi Therapeutics Market Size by Application (2016-2027)
    10.4 Middle East & Africa Antisense & RNAi Therapeutics Market Size by Country
        10.4.1 Middle East & Africa Antisense & RNAi Therapeutics Market Size by Country (2016-2021)
        10.4.2 Middle East & Africa Antisense & RNAi Therapeutics Market Size by Country (2022-2027)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE

11 Key Players Profiles
    11.1 Glaxo Smith Kline
        11.1.1 Glaxo Smith Kline Company Details
        11.1.2 Glaxo Smith Kline Business Overview
        11.1.3 Glaxo Smith Kline Antisense & RNAi Therapeutics Introduction
        11.1.4 Glaxo Smith Kline Revenue in Antisense & RNAi Therapeutics Business (2016-2021)
        11.1.5 Glaxo Smith Kline Recent Development
    11.2 Sanofi Aventis / Genzyme
        11.2.1 Sanofi Aventis / Genzyme Company Details
        11.2.2 Sanofi Aventis / Genzyme Business Overview
        11.2.3 Sanofi Aventis / Genzyme Antisense & RNAi Therapeutics Introduction
        11.2.4 Sanofi Aventis / Genzyme Revenue in Antisense & RNAi Therapeutics Business (2016-2021)
        11.2.5 Sanofi Aventis / Genzyme Recent Development
    11.3 Isis Pharmaceuticals/ Ionis Pharmaceuticals
        11.3.1 Isis Pharmaceuticals/ Ionis Pharmaceuticals Company Details
        11.3.2 Isis Pharmaceuticals/ Ionis Pharmaceuticals Business Overview
        11.3.3 Isis Pharmaceuticals/ Ionis Pharmaceuticals Antisense & RNAi Therapeutics Introduction
        11.3.4 Isis Pharmaceuticals/ Ionis Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2016-2021)
        11.3.5 Isis Pharmaceuticals/ Ionis Pharmaceuticals Recent Development
    11.4 Arbutus Biopharma Ltd.
        11.4.1 Arbutus Biopharma Ltd. Company Details
        11.4.2 Arbutus Biopharma Ltd. Business Overview
        11.4.3 Arbutus Biopharma Ltd. Antisense & RNAi Therapeutics Introduction
        11.4.4 Arbutus Biopharma Ltd. Revenue in Antisense & RNAi Therapeutics Business (2016-2021)
        11.4.5 Arbutus Biopharma Ltd. Recent Development
    11.5 Silence Therapeutics
        11.5.1 Silence Therapeutics Company Details
        11.5.2 Silence Therapeutics Business Overview
        11.5.3 Silence Therapeutics Antisense & RNAi Therapeutics Introduction
        11.5.4 Silence Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2016-2021)
        11.5.5 Silence Therapeutics Recent Development
    11.6 Bio-Path Holdings Inc.
        11.6.1 Bio-Path Holdings Inc. Company Details
        11.6.2 Bio-Path Holdings Inc. Business Overview
        11.6.3 Bio-Path Holdings Inc. Antisense & RNAi Therapeutics Introduction
        11.6.4 Bio-Path Holdings Inc. Revenue in Antisense & RNAi Therapeutics Business (2016-2021)
        11.6.5 Bio-Path Holdings Inc. Recent Development
    11.7 Calando Pharmaceuticals
        11.7.1 Calando Pharmaceuticals Company Details
        11.7.2 Calando Pharmaceuticals Business Overview
        11.7.3 Calando Pharmaceuticals Antisense & RNAi Therapeutics Introduction
        11.7.4 Calando Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2016-2021)
        11.7.5 Calando Pharmaceuticals Recent Development
    11.8 ICo Therapeutics
        11.8.1 ICo Therapeutics Company Details
        11.8.2 ICo Therapeutics Business Overview
        11.8.3 ICo Therapeutics Antisense & RNAi Therapeutics Introduction
        11.8.4 ICo Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2016-2021)
        11.8.5 ICo Therapeutics Recent Development
    11.9 Quark Pharmaceuticals
        11.9.1 Quark Pharmaceuticals Company Details
        11.9.2 Quark Pharmaceuticals Business Overview
        11.9.3 Quark Pharmaceuticals Antisense & RNAi Therapeutics Introduction
        11.9.4 Quark Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2016-2021)
        11.9.5 Quark Pharmaceuticals Recent Development
    11.10 Rexhan Pharmaceuticals
        11.10.1 Rexhan Pharmaceuticals Company Details
        11.10.2 Rexhan Pharmaceuticals Business Overview
        11.10.3 Rexhan Pharmaceuticals Antisense & RNAi Therapeutics Introduction
        11.10.4 Rexhan Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2016-2021)
        11.10.5 Rexhan Pharmaceuticals Recent Development
    11.11 Biomarin/Prosensa
        11.11.1 Biomarin/Prosensa Company Details
        11.11.2 Biomarin/Prosensa Business Overview
        11.11.3 Biomarin/Prosensa Antisense & RNAi Therapeutics Introduction
        11.11.4 Biomarin/Prosensa Revenue in Antisense & RNAi Therapeutics Business (2016-2021)
        11.11.5 Biomarin/Prosensa Recent Development
    11.12 Regulus Therapeutics
        11.12.1 Regulus Therapeutics Company Details
        11.12.2 Regulus Therapeutics Business Overview
        11.12.3 Regulus Therapeutics Antisense & RNAi Therapeutics Introduction
        11.12.4 Regulus Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2016-2021)
        11.12.5 Regulus Therapeutics Recent Development
    11.13 Rxi Pharmaceuticals
        11.13.1 Rxi Pharmaceuticals Company Details
        11.13.2 Rxi Pharmaceuticals Business Overview
        11.13.3 Rxi Pharmaceuticals Antisense & RNAi Therapeutics Introduction
        11.13.4 Rxi Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2016-2021)
        11.13.5 Rxi Pharmaceuticals Recent Development
    11.14 Silenseed
        11.14.1 Silenseed Company Details
        11.14.2 Silenseed Business Overview
        11.14.3 Silenseed Antisense & RNAi Therapeutics Introduction
        11.14.4 Silenseed Revenue in Antisense & RNAi Therapeutics Business (2016-2021)
        11.14.5 Silenseed Recent Development
    11.15 Dicerna Pharmaceuticals
        11.15.1 Dicerna Pharmaceuticals Company Details
        11.15.2 Dicerna Pharmaceuticals Business Overview
        11.15.3 Dicerna Pharmaceuticals Antisense & RNAi Therapeutics Introduction
        11.15.4 Dicerna Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2016-2021)
        11.15.5 Dicerna Pharmaceuticals Recent Development
    11.16 Sirnaomics Inc.
        11.16.1 Sirnaomics Inc. Company Details
        11.16.2 Sirnaomics Inc. Business Overview
        11.16.3 Sirnaomics Inc. Antisense & RNAi Therapeutics Introduction
        11.16.4 Sirnaomics Inc. Revenue in Antisense & RNAi Therapeutics Business (2016-2021)
        11.16.5 Sirnaomics Inc. Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details
List of Tables
    Table 1. Global Antisense & RNAi Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
    Table 2. Key Players of RNA Interference
    Table 3. Key Players of SiRNA
    Table 4. Key Players of MiRNA
    Table 5. Key Players of Antisense RNA
    Table 6. Global Antisense & RNAi Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
    Table 7. Global Antisense & RNAi Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
    Table 8. Global Antisense & RNAi Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
    Table 9. Global Antisense & RNAi Therapeutics Market Share by Regions (2016-2021)
    Table 10. Global Antisense & RNAi Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
    Table 11. Global Antisense & RNAi Therapeutics Market Share by Regions (2022-2027)
    Table 12. Antisense & RNAi Therapeutics Market Trends
    Table 13. Antisense & RNAi Therapeutics Market Drivers
    Table 14. Antisense & RNAi Therapeutics Market Challenges
    Table 15. Antisense & RNAi Therapeutics Market Restraints
    Table 16. Global Antisense & RNAi Therapeutics Revenue by Players (2016-2021) & (US$ Million)
    Table 17. Global Antisense & RNAi Therapeutics Market Share by Players (2016-2021)
    Table 18. Global Top Antisense & RNAi Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antisense & RNAi Therapeutics as of 2020)
    Table 19. Ranking of Global Top Antisense & RNAi Therapeutics Companies by Revenue (US$ Million) in 2020
    Table 20. Global 5 Largest Players Market Share by Antisense & RNAi Therapeutics Revenue (CR5 and HHI) & (2016-2021)
    Table 21. Key Players Headquarters and Area Served
    Table 22. Key Players Antisense & RNAi Therapeutics Product Solution and Service
    Table 23. Date of Enter into Antisense & RNAi Therapeutics Market
    Table 24. Mergers & Acquisitions, Expansion Plans
    Table 25. Global Antisense & RNAi Therapeutics Market Size by Type (2016-2021) (US$ Million)
    Table 26. Global Antisense & RNAi Therapeutics Revenue Market Share by Type (2016-2021)
    Table 27. Global Antisense & RNAi Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
    Table 28. Global Antisense & RNAi Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
    Table 29. Global Antisense & RNAi Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
    Table 30. Global Antisense & RNAi Therapeutics Revenue Market Share by Application (2016-2021)
    Table 31. Global Antisense & RNAi Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
    Table 32. Global Antisense & RNAi Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
    Table 33. North America Antisense & RNAi Therapeutics Market Size by Type (2016-2021) (US$ Million)
    Table 34. North America Antisense & RNAi Therapeutics Market Size by Type (2022-2027) & (US$ Million)
    Table 35. North America Antisense & RNAi Therapeutics Market Size by Application (2016-2021) (US$ Million)
    Table 36. North America Antisense & RNAi Therapeutics Market Size by Application (2022-2027) & (US$ Million)
    Table 37. North America Antisense & RNAi Therapeutics Market Size by Country (2016-2021) & (US$ Million) 
    Table 38. North America Antisense & RNAi Therapeutics Market Size by Country (2022-2027) & (US$ Million) 
    Table 39. Europe Antisense & RNAi Therapeutics Market Size by Type (2016-2021) (US$ Million)
    Table 40. Europe Antisense & RNAi Therapeutics Market Size by Type (2022-2027) & (US$ Million)
    Table 41. Europe Antisense & RNAi Therapeutics Market Size by Application (2016-2021) (US$ Million)
    Table 42. Europe Antisense & RNAi Therapeutics Market Size by Application (2022-2027) & (US$ Million)
    Table 43. Europe Antisense & RNAi Therapeutics Market Size by Country (2016-2021) & (US$ Million) 
    Table 44. Europe Antisense & RNAi Therapeutics Market Size by Country (2022-2027) & (US$ Million) 
    Table 45. Asia-Pacific Antisense & RNAi Therapeutics Market Size by Type (2016-2021) (US$ Million)
    Table 46. Asia-Pacific Antisense & RNAi Therapeutics Market Size by Type (2022-2027) & (US$ Million)
    Table 47. Asia-Pacific Antisense & RNAi Therapeutics Market Size by Application (2016-2021) (US$ Million)
    Table 48. Asia-Pacific Antisense & RNAi Therapeutics Market Size by Application (2022-2027) & (US$ Million)
    Table 49. Asia-Pacific Antisense & RNAi Therapeutics Market Size by Region (2016-2021) & (US$ Million) 
    Table 50. Asia-Pacific Antisense & RNAi Therapeutics Market Size by Region (2022-2027) & (US$ Million) 
    Table 51. Latin America Antisense & RNAi Therapeutics Market Size by Type (2016-2021) (US$ Million)
    Table 52. Latin America Antisense & RNAi Therapeutics Market Size by Type (2022-2027) & (US$ Million)
    Table 53. Latin America Antisense & RNAi Therapeutics Market Size by Application (2016-2021) (US$ Million)
    Table 54. Latin America Antisense & RNAi Therapeutics Market Size by Application (2022-2027) & (US$ Million)
    Table 55. Latin America Antisense & RNAi Therapeutics Market Size by Country (2016-2021) & (US$ Million) 
    Table 56. Latin America Antisense & RNAi Therapeutics Market Size by Country (2022-2027) & (US$ Million) 
    Table 57. Middle East & Africa Antisense & RNAi Therapeutics Market Size by Type (2016-2021) (US$ Million)
    Table 58. Middle East & Africa Antisense & RNAi Therapeutics Market Size by Type (2022-2027) & (US$ Million)
    Table 59. Middle East & Africa Antisense & RNAi Therapeutics Market Size by Application (2016-2021) (US$ Million)
    Table 60. Middle East & Africa Antisense & RNAi Therapeutics Market Size by Application (2022-2027) & (US$ Million)
    Table 61. Middle East & Africa Antisense & RNAi Therapeutics Market Size by Country (2016-2021) & (US$ Million) 
    Table 62. Middle East & Africa Antisense & RNAi Therapeutics Market Size by Country (2022-2027) & (US$ Million) 
    Table 63. Glaxo Smith Kline Company Details
    Table 64. Glaxo Smith Kline Business Overview
    Table 65. Glaxo Smith Kline Antisense & RNAi Therapeutics Product
    Table 66. Glaxo Smith Kline Revenue in Antisense & RNAi Therapeutics Business (2016-2021) & (US$ Million)
    Table 67. Glaxo Smith Kline Recent Development
    Table 68. Sanofi Aventis / Genzyme Company Details
    Table 69. Sanofi Aventis / Genzyme Business Overview
    Table 70. Sanofi Aventis / Genzyme Antisense & RNAi Therapeutics Product
    Table 71. Sanofi Aventis / Genzyme Revenue in Antisense & RNAi Therapeutics Business (2016-2021) & (US$ Million)
    Table 72. Sanofi Aventis / Genzyme Recent Development
    Table 73. Isis Pharmaceuticals/ Ionis Pharmaceuticals Company Details
    Table 74. Isis Pharmaceuticals/ Ionis Pharmaceuticals Business Overview
    Table 75. Isis Pharmaceuticals/ Ionis Pharmaceuticals Antisense & RNAi Therapeutics Product
    Table 76. Isis Pharmaceuticals/ Ionis Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2016-2021) & (US$ Million)
    Table 77. Isis Pharmaceuticals/ Ionis Pharmaceuticals Recent Development
    Table 78. Arbutus Biopharma Ltd. Company Details
    Table 79. Arbutus Biopharma Ltd. Business Overview
    Table 80. Arbutus Biopharma Ltd. Antisense & RNAi Therapeutics Product
    Table 81. Arbutus Biopharma Ltd. Revenue in Antisense & RNAi Therapeutics Business (2016-2021) & (US$ Million)
    Table 82. Arbutus Biopharma Ltd. Recent Development
    Table 83. Silence Therapeutics Company Details
    Table 84. Silence Therapeutics Business Overview
    Table 85. Silence Therapeutics Antisense & RNAi Therapeutics Product
    Table 86. Silence Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2016-2021) & (US$ Million)
    Table 87. Silence Therapeutics Recent Development
    Table 88. Bio-Path Holdings Inc. Company Details
    Table 89. Bio-Path Holdings Inc. Business Overview
    Table 90. Bio-Path Holdings Inc. Antisense & RNAi Therapeutics Product
    Table 91. Bio-Path Holdings Inc. Revenue in Antisense & RNAi Therapeutics Business (2016-2021) & (US$ Million)
    Table 92. Bio-Path Holdings Inc. Recent Development
    Table 93. Calando Pharmaceuticals Company Details
    Table 94. Calando Pharmaceuticals Business Overview
    Table 95. Calando Pharmaceuticals Antisense & RNAi Therapeutics Product
    Table 96. Calando Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2016-2021) & (US$ Million)
    Table 97. Calando Pharmaceuticals Recent Development
    Table 98. ICo Therapeutics Company Details
    Table 99. ICo Therapeutics Business Overview
    Table 100. ICo Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2016-2021) & (US$ Million)
    Table 101. ICo Therapeutics Recent Development
    Table 102. Quark Pharmaceuticals Company Details
    Table 103. Quark Pharmaceuticals Business Overview
    Table 104. Quark Pharmaceuticals Antisense & RNAi Therapeutics Product
    Table 105. Quark Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2016-2021) & (US$ Million)
    Table 106. Quark Pharmaceuticals Recent Development
    Table 107. Rexhan Pharmaceuticals Company Details
    Table 108. Rexhan Pharmaceuticals Business Overview
    Table 109. Rexhan Pharmaceuticals Antisense & RNAi Therapeutics Product
    Table 110. Rexhan Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2016-2021) & (US$ Million)
    Table 111. Rexhan Pharmaceuticals Recent Development
    Table 112. Biomarin/Prosensa Company Details
    Table 113. Biomarin/Prosensa Business Overview
    Table 114. Biomarin/Prosensa Antisense & RNAi Therapeutics Product
    Table 115. Biomarin/Prosensa Revenue in Antisense & RNAi Therapeutics Business (2016-2021) & (US$ Million)
    Table 116. Biomarin/Prosensa Recent Development
    Table 117. Regulus Therapeutics Company Details
    Table 118. Regulus Therapeutics Business Overview
    Table 119. Regulus Therapeutics Antisense & RNAi Therapeutics Product
    Table 120. Regulus Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2016-2021) & (US$ Million)
    Table 121. Regulus Therapeutics Recent Development
    Table 122. Rxi Pharmaceuticals Company Details
    Table 123. Rxi Pharmaceuticals Business Overview
    Table 124. Rxi Pharmaceuticals Antisense & RNAi Therapeutics Product
    Table 125. Rxi Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2016-2021) & (US$ Million)
    Table 126. Rxi Pharmaceuticals Recent Development
    Table 127. Silenseed Company Details
    Table 128. Silenseed Business Overview
    Table 129. Silenseed Antisense & RNAi Therapeutics Product
    Table 130. Silenseed Revenue in Antisense & RNAi Therapeutics Business (2016-2021) & (US$ Million)
    Table 131. Silenseed Recent Development
    Table 132. Dicerna Pharmaceuticals Company Details
    Table 133. Dicerna Pharmaceuticals Business Overview
    Table 134. Dicerna Pharmaceuticals Antisense & RNAi Therapeutics Product
    Table 135. Dicerna Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2016-2021) & (US$ Million)
    Table 136. Dicerna Pharmaceuticals Recent Development
    Table 137. Sirnaomics Inc. Company Details
    Table 138. Sirnaomics Inc. Business Overview
    Table 139. Sirnaomics Inc. Antisense & RNAi Therapeutics Product
    Table 140. Sirnaomics Inc. Revenue in Antisense & RNAi Therapeutics Business (2016-2021) & (US$ Million)
    Table 141. Sirnaomics Inc. Recent Development
    Table 142. Research Programs/Design for This Report
    Table 143. Key Data Information from Secondary Sources
    Table 144. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Antisense & RNAi Therapeutics Market Share by Type: 2020 VS 2027
    Figure 2. RNA Interference Features
    Figure 3. SiRNA Features
    Figure 4. MiRNA Features
    Figure 5. Antisense RNA Features
    Figure 6. Global Antisense & RNAi Therapeutics Market Share by Application: 2020 VS 2027
    Figure 7. Oncology Case Studies
    Figure 8. Cardiovascular Case Studies
    Figure 9. Renal Case Studies
    Figure 10. Neurodegenerative Case Studies
    Figure 11. Respiratory Case Studies
    Figure 12. Genetic Case Studies
    Figure 13. Infectious Diseases Case Studies
    Figure 14. Antisense & RNAi Therapeutics Report Years Considered
    Figure 15. Global Antisense & RNAi Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
    Figure 16. Global Antisense & RNAi Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
    Figure 17. Global Antisense & RNAi Therapeutics Market Share by Regions: 2020 VS 2027
    Figure 18. Global Antisense & RNAi Therapeutics Market Share by Regions (2022-2027)
    Figure 19. Global Antisense & RNAi Therapeutics Market Share by Players in 2020
    Figure 20. Global Top Antisense & RNAi Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antisense & RNAi Therapeutics as of 2020
    Figure 21. The Top 10 and 5 Players Market Share by Antisense & RNAi Therapeutics Revenue in 2020
    Figure 22. Global Antisense & RNAi Therapeutics Revenue Market Share by Type (2016-2021)
    Figure 23. Global Antisense & RNAi Therapeutics Revenue Market Share by Type (2022-2027)
    Figure 24. North America Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 25. North America Antisense & RNAi Therapeutics Market Share by Type (2016-2027)
    Figure 26. North America Antisense & RNAi Therapeutics Market Share by Application (2016-2027)
    Figure 27. North America Antisense & RNAi Therapeutics Market Share by Country (2016-2027)
    Figure 28. United States Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 29. Canada Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 30. Europe Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 31. Europe Antisense & RNAi Therapeutics Market Share by Type (2016-2027)
    Figure 32. Europe Antisense & RNAi Therapeutics Market Share by Application (2016-2027)
    Figure 33. Europe Antisense & RNAi Therapeutics Market Share by Country (2016-2027)
    Figure 34. Germany Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 35. France Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 36. U.K. Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 37. Italy Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 38. Russia Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 39. Nordic Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 40. Asia-Pacific Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 41. Asia-Pacific Antisense & RNAi Therapeutics Market Share by Type (2016-2027)
    Figure 42. Asia-Pacific Antisense & RNAi Therapeutics Market Share by Application (2016-2027)
    Figure 43. Asia-Pacific Antisense & RNAi Therapeutics Market Share by Region (2016-2027)
    Figure 44. China Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 45. Japan Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 46. South Korea Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 47. Southeast Asia Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 48. India Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 49. Australia Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 50. Latin America Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 51. Latin America Antisense & RNAi Therapeutics Market Share by Type (2016-2027)
    Figure 52. Latin America Antisense & RNAi Therapeutics Market Share by Application (2016-2027)
    Figure 53. Latin America Antisense & RNAi Therapeutics Market Share by Country (2016-2027)
    Figure 54. Mexico Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 55. Brazil Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 56. Middle East & Africa Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 57. Middle East & Africa Antisense & RNAi Therapeutics Market Share by Type (2016-2027)
    Figure 58. Middle East & Africa Antisense & RNAi Therapeutics Market Share by Application (2016-2027)
    Figure 59. Middle East & Africa Antisense & RNAi Therapeutics Market Share by Country (2016-2027)
    Figure 60. Turkey Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 61. Saudi Arabia Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 62. UAE Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 63. Glaxo Smith Kline Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2016-2021)
    Figure 64. Sanofi Aventis / Genzyme Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2016-2021)
    Figure 65. Isis Pharmaceuticals/ Ionis Pharmaceuticals Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2016-2021)
    Figure 66. Arbutus Biopharma Ltd. Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2016-2021)
    Figure 67. Silence Therapeutics Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2016-2021)
    Figure 68. Bio-Path Holdings Inc. Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2016-2021)
    Figure 69. Calando Pharmaceuticals Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2016-2021)
    Figure 70. ICo Therapeutics Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2016-2021)
    Figure 71. Quark Pharmaceuticals Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2016-2021)
    Figure 72. Rexhan Pharmaceuticals Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2016-2021)
    Figure 73. Biomarin/Prosensa Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2016-2021)
    Figure 74. Regulus Therapeutics Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2016-2021)
    Figure 75. Rxi Pharmaceuticals Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2016-2021)
    Figure 76. Silenseed Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2016-2021)
    Figure 77. Dicerna Pharmaceuticals Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2016-2021)
    Figure 78. Sirnaomics Inc. Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2016-2021)
    Figure 79. Bottom-up and Top-down Approaches for This Report
    Figure 80. Data Triangulation
    Figure 81. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Glaxo Smith Kline
Sanofi Aventis / Genzyme
Isis Pharmaceuticals/ Ionis Pharmaceuticals
Arbutus Biopharma Ltd.
Silence Therapeutics
Bio-Path Holdings Inc.
Calando Pharmaceuticals
ICo Therapeutics
Quark Pharmaceuticals
Rexhan Pharmaceuticals
Biomarin/Prosensa
Regulus Therapeutics
Rxi Pharmaceuticals
Silenseed
Dicerna Pharmaceuticals
Sirnaomics Inc.
Frequently Asked Questions
Antisense & RNAi Therapeutics report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Antisense & RNAi Therapeutics report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Antisense & RNAi Therapeutics report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Application Server

An application server is a modern form of platform middleware. It is system software that resides ... Read More